{"id":93879,"date":"2019-03-02T20:58:16","date_gmt":"2019-03-02T20:58:16","guid":{"rendered":"https:\/\/compumark.com\/?p=41298"},"modified":"2019-03-02T20:58:16","modified_gmt":"2019-03-02T20:58:16","slug":"whats-new-at-compumark-for-pharmaceutical-companies","status":"publish","type":"post","link":"https:\/\/clarivate.com\/intellectual-property\/blog\/whats-new-at-compumark-for-pharmaceutical-companies\/","title":{"rendered":"What\u2019s new at CompuMark for pharmaceutical companies"},"content":{"rendered":"<p>Developing a PTO-approved mark is a challenge for any organization. But for pharmaceutical companies, the journey doesn\u2019t end there. US Food and Drug Administration (FDA) requirements mean a second set of considerations. At CompuMark\u2122, we are committed to providing you with best-in-class products and services designed to navigate these challenges.<\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Developing a PTO-approved mark is a challenge for any organization. But for pharmaceutical companies, the journey doesn\u2019t end there. US Food and Drug Administration (FDA) requirements mean a second set&#8230;<\/p>\n","protected":false},"author":2,"featured_media":45626,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[706],"tags":[30,34],"class_list":["post-93879","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-trademarks","tag-compumark","tag-special-reports"],"acf":[],"lang":"en","translations":{"en":93879},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"pll_sync_post":[],"_links":{"self":[{"href":"https:\/\/clarivate.com\/intellectual-property\/wp-json\/wp\/v2\/posts\/93879","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/intellectual-property\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/clarivate.com\/intellectual-property\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/clarivate.com\/intellectual-property\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/clarivate.com\/intellectual-property\/wp-json\/wp\/v2\/comments?post=93879"}],"version-history":[{"count":0,"href":"https:\/\/clarivate.com\/intellectual-property\/wp-json\/wp\/v2\/posts\/93879\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/clarivate.com\/intellectual-property\/wp-json\/"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/intellectual-property\/wp-json\/wp\/v2\/media?parent=93879"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/clarivate.com\/intellectual-property\/wp-json\/wp\/v2\/categories?post=93879"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/clarivate.com\/intellectual-property\/wp-json\/wp\/v2\/tags?post=93879"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}